19:40:27 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-06 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-06-06 Ordinarie utdelning AZT 0.00 NOK
2024-06-05 Årsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-02-01 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-06-07 Ordinarie utdelning AZT 0.00 NOK
2023-06-06 Årsstämma 2023
2023-05-04 Kvartalsrapport 2023-Q1
2023-02-02 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-06-23 Årsstämma 2022
2022-05-27 Ordinarie utdelning AZT 0.00 NOK
2022-04-28 Kvartalsrapport 2022-Q1
2022-01-27 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning AZT 0.00 NOK
2021-05-20 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-01-28 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning AZT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-01-30 Bokslutskommuniké 2019
2020-01-06 Extra Bolagsstämma 2020
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning AZT 0.00 NOK
2019-05-15 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-01-30 Bokslutskommuniké 2018
2018-10-18 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-09 Ordinarie utdelning AZT 0.00 NOK
2018-05-07 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-01 Bokslutskommuniké 2017
2017-10-19 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-12 Ordinarie utdelning AZT 0.00 NOK
2017-05-11 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-02 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-12 Ordinarie utdelning AZT 0.00 NOK
2016-05-11 Årsstämma 2016
2016-04-19 Kvartalsrapport 2016-Q1
2016-02-11 Bokslutskommuniké 2015
2016-02-11 Kapitalmarknadsdag 2016
2015-11-03 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-13 Ordinarie utdelning AZT 0.00 NOK
2015-05-12 Årsstämma 2015
2015-05-05 Kvartalsrapport 2015-Q1
2015-02-17 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-13 Kvartalsrapport 2014-Q2
2014-05-15 Ordinarie utdelning AZT 0.00 NOK
2014-05-14 Årsstämma 2014
2014-04-30 Kvartalsrapport 2014-Q1
2014-02-14 Bokslutskommuniké 2013
2013-11-01 Kvartalsrapport 2013-Q3
2013-08-09 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-05-28 Ordinarie utdelning
2013-05-27 Årsstämma 2013
2013-05-07 Kvartalsrapport 2013-Q1
2013-02-01 Extra Bolagsstämma 2013
2013-01-07 Bokslutskommuniké 2012
2012-11-06 Kvartalsrapport 2012-Q3
2012-08-10 Kvartalsrapport 2012-Q2
2012-05-07 Ordinarie utdelning AZT 0.00 NOK
2012-05-07 Årsstämma 2012
2012-05-07 Kvartalsrapport 2012-Q1
2012-02-21 Bokslutskommuniké 2011
2011-11-08 Kvartalsrapport 2011-Q3
2011-08-10 Kvartalsrapport 2011-Q2
2011-05-13 Kvartalsrapport 2011-Q1
2011-05-13 Årsstämma 2011
2011-05-12 Ordinarie utdelning
2011-02-17 Bokslutskommuniké 2010
2010-11-12 Kvartalsrapport 2010-Q3
2010-08-10 Kvartalsrapport 2010-Q2
2010-05-11 Kvartalsrapport 2010-Q1
2010-05-04 Årsstämma 2010
2010-03-03 Bokslutskommuniké 2009

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
ArcticZymes Technologies är verksamma inom bioteknik. Bolaget specialiserar sig inom forskning och utveckling av läkemedel för behandling av autoimmuna sjukdomar. Störst inriktning återfinns inom utveckling av glukaner, framtagande av immunstimulerande medel, samt analys av enzymer. Visionen är att testa och utveckla medicinen för att sedan föra vidare dessa i användning för RNA och DNA processer. Bolaget gick tidigare under namnet Biotec Pharmacon och har sitt huvudkontor i Tromsö.
2022-08-18 07:00:16
Tromsø, Norway, 18[th] August 2022 - ArcticZymes Technologies (OSE: AZT)
reported sales of NOK 30.4 million (21.3) and an EBITDA of NOK 9.5 million (6.0)
for the second quarter of 2022.

Highlights from Q2 and first 6 months 2022

· ArcticZymes Technologies (AZT) had Q2 sales of NOK 30.4 million growing by
43% (Q2 2021: NOK 21.3 million) and sales for the first 6 months of NOK 79.5
million growing by 28% (6M 2021: NOK 62.2 million)
· AZT had a positive EBITDA for Q2 of NOK 9.5 million growing by 58% (Q2 2021:
NOK 6.0 million) and a positive EBITDA for the first six months of NOK 37.4
million growing by 18 % (6M 2021: NOK 31.8 million)
· Cash flow for Q2 was positive NOK 16.4 million (Q2 2021: NOK 13.5 million)
giving a cash balance of NOK 231.0 million (Q2 2021: NOK 176.8 million)
· Initiated the establishment of a Drug Master File (DMF) for the SAN HQ
enzyme
· Appointed Dirk Hahneiser as new Vice President of Business Development and
Marketing

CEO Jethro Holter comments:

"We are delighted with the quarterly performance and continued commercial
development of the business post-pandemic. Both Molecular Tools and
Biomanufacturing remain instrumental in delivering growth.

Furthermore, we welcome Dirk Hahneiser as new Vice President of Business
Development and Marketing to the team. We look forward to working closely with
Dirk in elevating commercial activities to the next level.

We would like to take this opportunity to thank DirkŽs predecessor, Dino
DiCamillo, for his outstanding achievements in delivering commercial growth of
the enzyme business over the last decade."

-Ends-

Presentation and Webcast

The Company will host a presentation for investors, analysts and media at 08:30
CET on Thursday, 18[th] August 2022 at Hotel Continental, Stortingsgata 24/26,
Oslo.

The presentation will be given by CEO, Jethro Holter and CFO, Børge Sørvoll

The presentation can also be followed as a live webcast from Hegnar TV on
www.arcticzymes.com or
https://channel.royalcast.com/landingpage/hegnarmedia/20220818_5/ It will be
possible to post questions through the webcast console.

The results, report and presentation for the second quarter and first half  2022
will be available on www.newsweb.no (https://protect
-eu.mimecast.com/s/ax_EC4xJkS8gx1SMlEBY?domain=newsweb.no) and on the Company's
homepage www.arcticzymes.com from 07:00 CET on 18[th] August 2022.

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Jethro Holter Tel: +47 46 85 91 46
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com